Clinical TrialParallelTreatment-Resistant Depression (TRD)EsketaminePlaceboNot yet recruiting

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

This Phase III, randomised, double-blind, placebo-controlled, parallel-group trial (n=348) will evaluate the efficacy, safety, and tolerability of esketamine nasal spray as monotherapy in adults with treatment-resistant depression. Participants with major depressive disorder who have not responded to at least 2 adequate antidepressant treatments in the current episode will receive esketamine 56 mg or 84 mg, or placebo, with the main outcome being change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score over the 4-week double-blind treatment phase. Participants will self-administer intranasal spray twice a week for 4 weeks: esketamine 56 mg, esketamine 84 mg, or placebo. Those who complete the double-blind phase on Day 28 may be eligible for an open-label phase in which they can receive esketamine 56 mg or 84 mg. The study requires a DSM-5 diagnosis of single-episode or recurrent major depressive disorder without psychotic features, with depression onset before age 55, and includes adults aged 18 years and older.

Ask Blossom about this trial
Target Enrollment
348 participants
Study Type
Phase III interventional
Design
Randomized, double Blind

Continue exploring

Continue exploring this trial

Move from the registry record to the most relevant public research context.

Compound research: EsketamineTopic research: Treatment-Resistant Depression (TRD)Research in Taiwan

Detailed Description

The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder \[MDD\] who have not responded to at least 2 different antidepressant treatments given at an adequate dose for an adequate duration in the current episode of depression).

Study Arms & Interventions

Esketamine 56 milligram (mg)

experimental

Participants will be randomized to receive double-blind (DB) treatment with esketamine 56 mg, twice a week for 4 weeks. Participants who complete the DB treatment phase on Day 28 may be eligible to participate in an open-label treatment phase and receive either esketamine 56 or 84 mg.

Interventions

  • Esketamine56 mg
    via Other• twice a week for 4 weeks
  • Esketamine84 mg
    via Other• twice a week for 4 weeks

Esketamine 84 mg

experimental

Participants will be randomized to receive DB treatment with esketamine 84 mg, twice a week for 4 weeks. Participants who complete the DB treatment phase on Day 28 may be eligible to participate in an open-label treatment phase and receive either esketamine 56 or 84 mg.

Interventions

  • Esketamine56 mg
    via Other• twice a week for 4 weeks
  • Esketamine84 mg
    via Other• twice a week for 4 weeks

Placebo

inactive

Participants will be randomized to receive DB treatment with placebo twice a week for 4 weeks. Participants who complete the DB treatment phase on Day 28 may be eligible to participate in an open-label treatment phase and receive either esketamine 56 mg or 84 mg.

Interventions

  • Esketamine56 mg
    via Other• twice a week for 4 weeks
  • Esketamine84 mg
    via Other• twice a week for 4 weeks
  • Placebo
    via Other• twice a week for 4 weeks

Participants

Ages
18 – ?
Sexes
Male & Female

Inclusion Criteria

  • Participant must meet the diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) (if single episode MDD, the duration of the episode must be greater than or equal to \[\>=\] 12 months) or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the mini international neuropsychiatric interview (MINI) as the primary diagnosis. Participant must have had the first onset of depression prior to 55 years of age
  • Participant must have had nonresponse (less than or equal to \[\<=\] 25 percent \[%\] improvement) to \>=2 oral antidepressant treatments in the current episode of depression, assessed using the massachusetts general hospital-antidepressant treatment response questionnaire (MGH-ATRQ), and confirmed by documented records (for example, medical/pharmacy/prescription records or a letter from a treating physician)
  • The participant's current major depressive episode, depression symptom severity, and antidepressant treatment response in the current depressive episode, must be confirmed by the state versus trait, assessability, face validity, ecological validity, rule of three P's (SAFER) Interview
  • Participant must be comfortable with self-administration of nasal spray medication and be able to follow the nasal spray administration instructions provided
  • A female participant of childbearing potential must have a negative highly sensitive serum (β-human chorionic gonadotropin \[β-hCG\]) at the start of screening and a negative urine pregnancy test must be obtained before the first dose of study drug on Day 1, prior to randomization

Exclusion Criteria

  • The participant has used ketamine/esketamine (lifetime)
  • The participant's depressive symptoms have demonstrated nonresponse in the current major depressive episode to an adequate course of treatment with electroconvulsive therapy (ECT), defined as at least 7 treatments with unilateral/bilateral ECT, or to adequate course of treatment with transcranial magnetic stimulation (TMS), defined as at least 4 weeks of treatment with 5 sessions per week
  • Participant has received vagal nerve stimulation (VNS) or deep brain stimulation (DBS) in the current episode of depression
  • Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase, per the investigator's clinical judgment or based on the columbia suicide severity rating scale (C-SSRS), corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation on the C-SSRS, or a history of suicidal behavior within the past year prior to the start of the screening phase. Participants reporting suicidal ideation with intent to act or suicidal behavior prior to the start of the double-blind treatment phase should be excluded
  • Participant has a history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months before the start of the screening phase. a. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
  • Participant has a current or history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)

Study Protocol, Arms & Participants

Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.

See Pro Plans

Study Details

Study Team

Sponsors & Collaborators

Locations

Taipei Medical University — Taipei, Taiwan

Your Personal Research Library

Go Pro to save trials, add notes, rate research, and organize custom shelves.

See Pro Plans